Contrary to the findings of our previous study, we found evidence of improvements to cardiometabolic risk factors (body weight, lipids, and insulin sensitivity) in the WD+CRS groups in the current study utilizing a more severe CRS intervention. The gene discussed is INS; the disease is Wilson disease.